Inhibikase Therapeutics (IKT) Reports In-Line Q2 EPS
Tweet
Share
E-mailGet Alerts IKT Hot Sheet
Join SI Premium – FREE
Inhibikase Therapeutics (NASDAQ: IKT) reported Q2 EPS of ($0.11), in-line with the analyst estimate of ($0.11).
For earnings history and earnings-related data on Inhibikase Therapeutics (IKT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA says convenience store sales trail broader retail channels
- Prenetics Global (PRE) Tops Q2 EPS by 18c
- iShares 20+ Year Treasury Bond ETF (TLT) call put ratio 1.3 calls to 1 put on 124K contracts
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
